| Entry |
|
|---|
| Name |
Letrozole (JAN/USP/INN);
Femara (TN)
|
|---|
| Product |
|
|---|
| Generic |
LETROZOLE (APP Pharmaceuticals), LETROZOLE (Accord Healthcare), LETROZOLE (Apotex Corp.), LETROZOLE (Breckenridge Pharmaceutical), LETROZOLE (Dr. Reddy's Laboratories Limited), LETROZOLE (INDICUS PHARMA LLC), LETROZOLE (Kremers Urban Pharmaceuticals), LETROZOLE (Mylan Pharmaceuticals), LETROZOLE (Physicians Total Care), LETROZOLE (Qualitest Pharmaceuticals), LETROZOLE (Rebel Distributors Corp), LETROZOLE (Roxane Laboratories), LETROZOLE (Sun Pharmaceutical Industries Limited), LETROZOLE (Teva Pharmaceuticals USA) |
|---|
| Formula |
C17H11N5
|
|---|
| Exact mass |
285.1014
|
|---|
| Mol weight |
285.3027
|
|---|
| Structure |
     |
|---|
| Activity |
|
|---|
| Remark |
Same as: Therapeutic category: ATC code: |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP2A6 [HSA: 1548]
|
|---|
| Interaction |
Genomic biomarker: ESR [HSA: 2099 2100] positive, PGR [HSA: 5241] positive
CYP inhibition: CYP2A6 [HSA: 1548]
 |
|---|
| Structure map |
| Antineoplastics - hormones |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D00964 Letrozole (JAN/USP/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BG Aromatase inhibitors
L02BG04 Letrozole
D00964 Letrozole (JAN/USP/INN)
USP drug classification [BR:br08302]
Antineoplastics
Aromatase Inhibitors, 3rd Generation
Letrozole
D00964 Letrozole (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases
aromatase [HSA:1588] [KO:K07434]
Letrozole [ATC:L02BG04]
D00964 Letrozole (JAN/USP/INN)
Antineoplastics [BR:br08308]
Hormones and hormone antagonist
Aromatase inhibitor
Letrozole [ATC:L02BG04]
D00964 Letrozole (JAN/USP/INN)
 |
|---|
| Other DBs |
CAS: 112809-51-5 PubChem: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 22
1 C1c C 25.6900 -19.1281
2 C8y C 26.8966 -19.8333
3 C8y C 24.4834 -19.8276
4 N4y N 25.6957 -17.7232
5 C8x C 26.8907 -21.2381
6 C8x C 28.1149 -19.1338
7 C8x C 24.4834 -21.2266
8 C8x C 23.2710 -19.1222
9 C8x C 24.5650 -16.9072
10 N5x N 26.8326 -16.9072
11 C8x C 28.1033 -21.9376
12 C8x C 29.3273 -19.8450
13 C8x C 23.2710 -21.9259
14 C8x C 22.0527 -19.8276
15 N5x N 25.0022 -15.5723
16 C8x C 26.4069 -15.5723
17 C8y C 29.3216 -21.2498
18 C8y C 22.0527 -21.2266
19 C3b C 30.5165 -21.9435
20 C3b C 20.8402 -21.9202
21 N3a N 31.7172 -22.6371
22 N3a N 19.6394 -22.6430
BOND 24
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 2
5 2 6 1
6 3 7 2
7 3 8 1
8 4 9 1
9 4 10 1
10 5 11 1
11 6 12 2
12 7 13 1
13 8 14 2
14 9 15 2
15 10 16 2
16 11 17 2
17 13 18 2
18 17 19 1
19 18 20 1
20 19 21 3
21 20 22 3
22 12 17 1
23 14 18 1
24 15 16 1
|
|---|
